This year, Gentian is proudly celebrating 20 years of innovating diagnostic efficiency. The company was started by the brothers Erling and Bård Sundrehagen in 2001. Having worked together during the founding of Axis (later Axis-Shield ltd, Alere inc. and now Abbott), they were eager to start a new, innovative venture in the diagnostics field.
Starting with finding the gap in the market
After speaking to laboratory professionals across Scandinavia, the brothers identified a gap in the IVD market for a high quality turbidimetric cystatin C immunoassay. Working from a small office in Central Moss, 50 km South of Oslo, Norway, the company launched the Gentian Cystatin C immunoassay in 2006. In 2008, the assay received FDA 510(k) clearance. Today the assay is used among leading institutions across the globe.
Following its success in human diagnostics, Gentian expanded into veterinary medicine in 2012 with its Canine CRP Immunoassay.
Developing multi-platform assays
Gentian’s multi-platform assays are adapted for use on instruments that are available in centralised laboratories all over the world. Over the years, the company has established itself as a leader in Particle-Enhanced Turbidimetric Immunoassay (PETIA) development. With an open channel approach, Gentian products can be used without additional investment in instrumentation.
Working out of Norway
Having outgrown its original facility, the company opened up a dedicated laboratory, production and office space in Moss in 2011, which was further expanded in 2016. By the end of 2021, the company hopes to complete yet another expansion of the facility, which would provide the capacity needed to meet the growing demand for its products. Production, R&D, marketing, and distribution of immunoassays are all performed at the headquarters in Norway.
Expanding the global reach
To expand Gentian' global reach, the Beijing representative office was opened in 2009 and Gentian USA Inc. was established in 2012. In 2016, the Swedish subsidiary Gentian Diagnostics AB was established to take charge of product distribution in Sweden.
Existing and future product portfolio
Gentian’s goal is to increase diagnostic efficiency and decrease the cost of diagnostic testing in the areas of inflammation, severe infection, kidney failure, congestive heart failure and veterinary healthcare. The current portfolio includes cystatin C (510(k)-cleared/CE marked), plasma and serum calprotectin (CE marked), canine CRP and faecal calprotectin and pancreatic assays.
A SARS-CoV-2 antibody test will be launched end of 2021. This antibody test can assist with identifying patients with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection or a successful response to vaccination. Gentian will bring SARS-CoV-2 serology testing to automated, open-access clinical chemistry platforms, increasing both the testing capacity (up to 2000 tests/hour) and the laboratory efficiency. Most other antibody tests are available only on closed immunochemistry systems, that are not as widely available.
In Q1 2022 Gentian will to launch the first turbidimetric NT-proBNP immunoassay. The assay will be positioned as an aid in the diagnosis, monitoring and assessment of severity in individuals suspected of having congestive heart failure (CHF). The test will deliver results with the same diagnostic accuracy as tests based on chemiluminescence technology that currently dominate the market. It is Gentian’s proprietary antibody and nanoparticle technology that allows for comparable, consistent, biotin interference-free measurement of NT-proBNP concentrations on high-volume clinical chemistry analysers that are widely available on the market.
Get in touch
Interested to learn more about Gentian, partnership opportunities or our products? Fill out the form below or send an email to firstname.lastname@example.org